Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome

Summary

Phase 2, open-label, single-arm, multi-centre study evaluating the long term safety and tolerability of PBI-4050 in subjects with Alström Syndrome who have completed a preceding ProMetic-sponsored Alström Syndrome study with PBI-4050.

Timeline

Start

2017-10-09

Primary completion

2020-05-08

Completion

2020-05-08

Drugs

Indications